Are you Dr. Dinney?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 42 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Colin Dinney, MD is a urologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center and is a Professor at Division of Surgery.
Education & Training
University of ManitobaClass of 1982
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 1991 - 2026
OK State Medical License 2020 - 2021
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer Start of enrollment: 1998 Nov 01
- Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Start of enrollment: 2001 Jul 01
- Screening for Bladder Cancer Start of enrollment: 2007 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 700 citationsA Consensus Molecular Classification of Muscle-invasive Bladder Cancer.Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, Gottfrid Sjödahl, A. Gordon Robertson
European Urology. 2020-04-01 - 1205 citationsIdentification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline ChemotherapyWoonyoung Choi, Sima P. Porten, Seungchan Kim, Daniel L. Willis, Elizabeth R. Plimack
Cancer Cell. 2014-02-10 - 50 citationsPhase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder CancerAnita L. Sabichi, Seth P. Lerner, E. Neely Atkinson, H. Barton Grossman, Nancy P. Caraway
Clinical Cancer Research. 2008-01-01
Press Mentions
Β-arrestins Regulate Stem Cell-like Phenotype and Response to Chemotherapy in Bladder CancerFebruary 20th, 2020
Ferring + Blackstone Life Sciences Launch New Oncology Company to Further Treatment for Invasive Bladder CancerNovember 25th, 2019
One of the World’s Largest Private Equity Firms Enters Targets Unmet Need for Bladder Cancer with Swiss PharmaNovember 25th, 2019- Join now to see all
Grant Support
- Developmental Research ProgramNational Cancer Institute2008–2010
- Career Developement ProgramNational Cancer Institute2008–2010
- Administrative CoreNational Cancer Institute2008–2010
- Spore In Genitourinary CancerNational Cancer Institute2006–2010
- M. D. Anderson Cancer Spore In Genitourinary CancersNational Cancer Institute2001–2005
- Biology Of Bladder Cancer MetastasesNational Cancer Institute1996–2000
Professional Memberships
- Member
